专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2023061930A1 THERAPEUTIC RNA FOR LUNG CANCER 审中-公开
公开(公告)号：WO2023061930A1
公开(公告)日：2023-04-20
申请号：PCT/EP2022/078081
申请日：2022-10-10
申请人： BIONTECH SE
发明人： SAHIN, Ugur
IPC分类号： A61K39/12 , A61K39/00
摘要： This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

32. 发明申请

WO2023061550A1 THERAPEUTIC RNA FOR LUNG CANCER 审中-公开
公开(公告)号：WO2023061550A1
公开(公告)日：2023-04-20
申请号：PCT/EP2021/078022
申请日：2021-10-11
申请人： BIONTECH SE , TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
发明人： SAHIN, Ugur , WEBER, David , WALTER, Carina , BAREA ROLDAN, Diana , KUNER, Ruprecht , HEIN, Melanie , SUCHAN, Martin , KISSLER, Verena
IPC分类号： A61K39/00
摘要： This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

33. 发明申请

WO2023006920A1 COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMA 审中-公开
公开(公告)号：WO2023006920A1
公开(公告)日：2023-02-02
申请号：PCT/EP2022/071276
申请日：2022-07-28
申请人： BIONTECH SE
发明人： SAHIN, Ugur , JABULOWSKY, Robert A. , SCHWARCK-KOKARAKIS, Doreen , TÜRECI, Özlem
IPC分类号： A61K39/00 , A61K39/395 , A61P35/00 , C07K16/28
摘要： The present disclosure provides compositions and methods for treatment of melanoma.

34. 发明申请

WO2022136266A1 THERAPEUTIC RNA FOR TREATING CANCER 审中-公开
公开(公告)号：WO2022136266A1
公开(公告)日：2022-06-30
申请号：PCT/EP2021/086778
申请日：2021-12-20
申请人： BIONTECH SE
发明人： SAHIN, Ugur , MUIK, Alexander , KRANZ, Lena Mareen , VORMEHR, Mathias , FELLERMEIER-KOPF, Sina , DIEKMANN, Jan , EISEL, David
IPC分类号： A61K31/7105 , A61K38/20 , C07K14/54 , C07K14/55 , C07K14/765 , C12N15/62
摘要： This disclosure relates to the field of therapeutic RNA to treat cancer, in particular advanced solid tumors such as metastatic (Stage IV) or unresectable localized cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers. Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

35. 发明申请

WO2022135667A1 THERAPEUTIC RNA FOR TREATING CANCER 审中-公开
公开(公告)号：WO2022135667A1
公开(公告)日：2022-06-30
申请号：PCT/EP2020/087468
申请日：2020-12-21
申请人： BIONTECH SE
发明人： VORMEHR, Mathias , KRANZ, Lena Mareen , SAHIN, Ugur , EISEL, David
IPC分类号： A61K39/00
摘要： This disclosure relates to the field of therapeutic RNA to treat cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers. Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

36. 发明申请

WO2021214204A1 RNA CONSTRUCTS AND USES THEREOF 审中-公开
公开(公告)号：WO2021214204A1
公开(公告)日：2021-10-28
申请号：PCT/EP2021/060508
申请日：2021-04-22
申请人： BIONTECH SE
发明人： SAHIN, Ugur , GÜLER, Alptekin , KUHN, Andreas , MUIK, Alexander , VOGEL, Annette , WALZER, Kerstin , WITZEL, Sonja , HEIN, Stephanie , TÜRECI, Özlem , BOROS, Gábor , MAHINY, Azita Josefine , REINHOLZ, Jonas , KARIKO, Katalin
IPC分类号： C12N15/11 , A61K39/215 , A61K45/06 , C12N15/00 , C12N15/10 , C07H21/00 , C07H21/02
摘要： Disclosed herein are RNA polynucleotides comprising a 5' Cap, a 5' UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.

37. 发明申请

WO2021213924A1 CORONAVIRUS VACCINE 审中-公开
公开(公告)号：WO2021213924A1
公开(公告)日：2021-10-28
申请号：PCT/EP2021/059947
申请日：2021-04-16
申请人： BIONTECH SE
发明人： SAHIN, Ugur , GÜLER, Alptekin , KUHN, Andreas , MUIK, Alexander , VOGEL, Annette , WALZER, Kerstin , WITZEL, Sonja , HEIN, Stephanie , TÜRECI, Özlem
IPC分类号： A61K39/12 , A61K39/00
摘要： This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. These methods and agents are, in particular, useful for the prevention or treatment of coronavirus infection. Administration of RNA disclosed herein to a subject can protect the subject against coronavirus infection. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen. Administering to the subject RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for inducing an immune response against vaccine antigen (and disease-associated antigen) in the subject. In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China and it became clear that a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was the underlying cause. The genetic sequence of SARS-CoV-2 became available to the WHO and public (MN908947.3) and the virus was categorized into the betacoronavirus subfamily. By sequence analysis, the phylogenetic tree revealed a closer relationship to severe acute respiratory syndrome (SARS) virus isolates than to another coronavirus infecting humans, namely the Middle East respiratory syndrome (MERS) virus. On February 2nd, a total of 14'557 cases were globally confirmed in 24 countries including Germany and a subsequent self-sustaining, human-to-human virus spread resulted in that SARS-CoV-2 became a global epidemic.

38. 发明申请

WO2021198258A1 TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION 审中-公开
公开(公告)号：WO2021198258A1
公开(公告)日：2021-10-07
申请号：PCT/EP2021/058297
申请日：2021-03-30
申请人： BIONTECH SE , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
发明人： SAHIN, Ugur , KRANZ, Lena Mareen , DIKEN, Mustafa , HILSCHER, Lina , KREITER, Sebastian
IPC分类号： A61K39/39 , A61K39/00 , A61P35/00 , A61K2039/53 , A61K2039/55511 , A61K2039/55522 , A61K39/0011
摘要： The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. Specifically, the present disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or protein comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding vaccine antigen; and (ii) an immune stimulant or RNA encoding an immunostimulant. Administering to the subject non-immunogenic RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for stimulation, priming and/or expansion of immune effector cells and, thus, may induce an immune response against vaccine antigen (and disease-associated antigen) in the subject.

39. 发明申请

WO2021198157A1 RNA COMPOSITIONS TARGETING CLAUDIN-18.2 审中-公开
公开(公告)号：WO2021198157A1
公开(公告)日：2021-10-07
申请号：PCT/EP2021/058112
申请日：2021-03-29
申请人： BIONTECH SE
发明人： SAHIN, Ugur , LINDEMANN, Claudia , DIEKMANN, Jan , BRETTSCHNEIDER, Kerstin , BÄHR-MAHMUD, Hayat , ELLINGHAUS, Ursula , FISCHER, Leyla , STADLER, Christiane , TÜRECI, Özlem
IPC分类号： C07K16/28 , A61K9/10 , A61K2039/505 , A61K2039/53 , A61K9/0019 , A61K9/5123 , A61K9/5146 , C07K2317/33 , C07K2317/732 , C07K2317/734 , C07K2317/94
摘要： The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g, but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g, in combination with a chemotherapeutic agent).

40. 发明申请

WO2021155916A1 TREATMENT INVOLVING ANTIGEN VACCINATION AND BINDING AGENTS BINDING TO PD-L1 AND CD137 审中-公开
公开(公告)号：WO2021155916A1
公开(公告)日：2021-08-12
申请号：PCT/EP2020/052774
申请日：2020-02-04
申请人： BIONTECH SE
发明人： SAHIN, Ugur , MUIK, Alexander , KRANZ, Lena , VORMEHR, Mathias
IPC分类号： A61K39/00 , C07K14/705 , A61K39/395 , C07K16/28
摘要： The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising providing to the subject a peptide or protein vaccine and a binding agent, such as a bispecific antibody, binding to PD-L1 and CD137, such as human PD-L1 and human CD137, e.g., by coadministering to the subject a peptide or protein used for vaccination or a polynucleotide, in particular RNA, encoding a peptide or protein used for vaccination, and a binding agent binding to PD-L1 and CD137 or a polynucleotide, in particular RNA, encoding a binding agent binding to PD-L1 and CD137. The present disclosure further relates to medical preparations useful in the methods disclosed herein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式